Spruce Biosciences, Inc. (SPRB) stock
Close on Nov 11, 2026Market cap $132.78MP/E –Yield –
Spruce Biosciences, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. At the latest close the market valued the company at $132.78M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $132.78M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$67.15M
- EPS, diluted
- -$35.41
- Book value per share
- $23.50
- Diluted shares
- 3M
Trading
- Next earnings
- Mar 8, 2027 (estimated, before the open)
- Previous close
- $46.66
- Open
- $47.40
- Day's range
- $45.44 – $47.40
- Volume
- 50,234
- Average volume (20 days)
- 75,296
- Index membership
- Russell 2000 (since Jun 2026)
- 52-week range
- $38.06 – $127.90
- RSI (14 days)
- 50.9
- Volatility (1 year)
- 84.1%
- Relative volume
- 0.64×
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SPRB | S&P 500 | Difference | SPRB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.9% | -2.4% | +7.3 pts | ||
| 3 months | -0.5% | -1.2% | +0.7 pts | ||
| Year to date | -47.0% | +12.3% | −59.3 pts | ||
| 1 year | -59.0% | +12.4% | −71.4 pts | ||
| 3 years | -41.3% | +78.8% | −120.2 pts | -16.3% | +21.4% |
| 5 years | -86.0% | +75.2% | −161.2 pts | -32.5% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Spruce Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
About Spruce Biosciences
Pharmaceutical Preparations
Spruce Biosciences is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical needs. The company's portfolio features product candidates targeting serious conditions with established biological pathways, where approved treatments are unavailable or current options remain suboptimal. Its lead candidate, tralesinidase alfa enzyme replacement therapy, is an investigational fusion protein intended to restore alpha-N-acetylglucosaminidase enzyme activity in the central nervous system for patients with Mucopolysaccharidosis Type IIIB.
Company profile, executives and historySpruce Biosciences stock: common questions
What is Spruce Biosciences's stock price?
SPRB closed at $46.20 on Nov 11, 2026, down 1.00% on the day. Over the past 52 weeks it traded between $38.06 and $127.90.
What is Spruce Biosciences's market cap?
Spruce Biosciences was worth $132.78M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SPRB's P/E ratio?
Spruce Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$35.41), so it has no meaningful P/E ratio.
How much revenue does Spruce Biosciences make?
Spruce Biosciences reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Spruce Biosciences pay a dividend?
No. Spruce Biosciences has not paid a cash dividend over the last twelve months.
When does Spruce Biosciences report earnings next?
Spruce Biosciences is expected to report Q4 FY2026 results on Mar 8, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has SPRB stock performed over the past year?
Including dividends, SPRB returned -59.0% over the past year, against +12.4% for the S&P 500.
How many SPRB shares are sold short?
1M shares were sold short at the latest FINRA report, 65.33% of the float, or 7.0 days of average trading volume.
Who are Spruce Biosciences's competitors?
Companies most similar to Spruce Biosciences by business, industry and size include MNOV, IGC, NGNE, MREO, SPRC.
See a number that looks wrong?